Cian Healthcare Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Cian Healthcare Ltd is ₹ 8.26 as of 10 Apr 15:30 . The P/E Ratio of Cian Healthcare Ltd changed from 562.5 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Cian Healthcare Ltd changed from ₹ 26.28 crore on March 2021 to ₹ 8.62 crore on March 2025 . This represents a CAGR of -19.98% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Cian Healthcare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Cian Healthcare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Cian Healthcare Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Cian Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Cian Healthcare Ltd

Cian Healthcare Limited was originally incorporated as a Private Limited Company with the name of 'Cian Healthcare Private Limited' on January 07, 2003.
Subsequently, the Company was converted into a Public Limited Company and the name of the Company was changed to 'Cian Healthcare Limited' pursuant to a fresh Certificate of Incorporation granted by the Registrar of Companies, Pune dated November 30, 2018. The Company is a certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products.
The Company complies with the standard manufacturing practices as laid down by the World Health Organization and is also certified by the Food and Drug Control Administration. The Company started manufacturing unit at Roorkee in Uttarakhand in 2013.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Cian Healthcare Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Cian Healthcare Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Cian Healthcare Ltd is 20 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,069 Cr

What are the key factors driving the stock performance of Cian Healthcare Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Cian Healthcare Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cian Healthcare Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 6, 2026, the Cian Healthcare Ltd stock price is INR ₹8.26. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2424.3.

How do dividend payouts of Cian Healthcare Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cian Healthcare Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.